Copyright ©The Author(s) 2020.
World J Gastroenterol. Jul 7, 2020; 26(25): 3562-3576
Published online Jul 7, 2020. doi: 10.3748/wjg.v26.i25.3562
Figure 3
Figure 3 Comparison of the effect of enteral (proximal or distal) and intravenous (i. v.) isoglycemic glucose administrations on plasma incretin hormone, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretions in healthy subjects and subjects with type 2 diabetes mellitus. A and B: Glucose-dependent insulinotropic polypeptide; C and D: Glucagon-like peptide-1. Asterisk represents P < 0.05 for proximal vs distal enteral glucose infusion; Numbersign represents P < 0.05 for proximal enteral vs corresponding i.v. glycemic glucose infusion; Delta represents P < 0.05 for distal enteral vs corresponding i.v. glycemic glucose infusion. Data are presented as mean ± SEM. GLP-1: Glucagon-like peptide 1; GIP: Glucose-dependent insulinotropic polypeptide; T2DM: Type 2 diabetes mellitus. Citation: Zhang X, Young RL, Bound M, Hu S, Jones KL, Horowitz M, Rayner CK, Wu T. Comparative Effects of Proximal and Distal Small Intestinal Glucose Exposure on Glycemia, Incretin Hormone Secretion, and the Incretin Effect in Health and Type 2 Diabetes. Diabetes Care 2019; 42: 520-528. Copyright© The Authors 2019. Published by American Diabetes Association.